About S&E bio
S&E bio is a Healthcare company based in Seoul (South Korea) founded in 2019. Cell therapies for neurological disorders are developed using extracellular vesicles. S&E bio has raised $7.34 million across 1 funding round from investors including Korea Investment Holdings, KB Investment and Company K Partners. Its chief executive, as recorded, is Oh Young Bang. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells.
Company details
SE bio was founded in 2019 in Seoul, South Korea, within the biotechnology sector. Mesenchymal stem cell-derived extracellular vesicles are developed as therapeutics by the company for conditions including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Operations center on advancing these cell-based treatments for neurological applications, with leadership provided by CEO Oh Young Bang.
- Headquarters Seoul, South Korea
- SectorsHealthcare
- Phone•••• ••••
- Website snebio.com
- Total Equity Funding$7.34M (USD)
in 1 rounds
- Latest Funding Round$7.34M (USD), Series A
Dec 2022
- InvestorsKorea Investment Holdings
& 3 more
Funding Insights of S&E bio
S&E bio has successfully raised a total of $7.34M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.34 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.34M
- Total Rounds 1
- Last Round Series A — $7.34M
- First Round $7.34M
(Dec 2022)
- Investors Count 4
All 1 funding rounds of SE bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $7.34M | Series A | – | KB Investment, Korea Investment Holdings | – |
4 investors in total: 4 institutional.
Investors in S&E bio
S&E bio has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Korea Investment Holdings, KB Investment and Company K Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
Investment holding firm established in Seoul in 2003. | 2003 | koreainvestment.com | Seoul, South Korea | |
Venture capital firm investing in tech startups | 2006 | kpartners.co.kr | Seoul, South Korea | |
| lski.co.kr |
Investor details for SE bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of S&E bio
1 people are tracked at S&E bio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Oh Young Bang | CEO | Leadership |
Complete people profiles for S&E bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of S&E bio
2 dated milestones of S&E bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded S&E bio is founded.
- Funding First funding round of $7.3M.
Web traffic of S&E bio
The website of S&E bio (snebio.com) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 39% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about S&E Bio
Complete news archive for SE bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about S&E bio
S&E bio was founded in 2019 and raised its 1st funding round 3 years after it was founded.
S&E bio is headquartered in Seoul, South Korea.
Oh Young Bang is the CEO of S&E bio, as recorded in our data.
S&E bio is a funded company, having raised a total of $7.34M across 1 funding round to date. The company's 1st funding round was a Series A of $7.34M, raised on Dec 2022.
SE bio was founded in 2019 in Seoul, South Korea, within the biotechnology sector. Mesenchymal stem cell-derived extracellular vesicles are developed as therapeutics by the company for conditions including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Operations center on advancing these cell-based treatments for neurological applications, with leadership provided by CEO Oh Young Bang.
S&E bio has 4 investors. Key investors include Korea Investment Holdings, KB Investment, Company K Partners, and LSK investment.